Literature DB >> 1646503

Virus inactivation during production of intravenous immunoglobulin.

C Kempf1, P Jentsch, B Poirier, F Barré-Sinoussi, J J Morgenthaler, A Morell, D Germann.   

Abstract

The effect of pepsin treatment at pH 4 on the infectivity of several enveloped viruses was assessed under the conditions used during the production of intravenous immunoglobulins. It was shown that the prototypes of four virus families--human immunodeficiency virus (Lentivirinae), herpes simplex virus type 1 and human cytomegalovirus (Herpesviridae), Semliki Forest virus (Togaviridae), and vesicular stomatitis virus (Rhabdoviridae)--were inactivated by this procedure. With vesicular stomatitis virus as a model, the contributions of both low pH and pepsin were demonstrated, and pepsin had a synergistic or additive action.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1646503     DOI： 10.1046/j.1537-2995.1991.31591263197.x

Source DB:  PubMed          Journal:  Transfusion        ISSN： 0041-1132            Impact factor:   3.157


  10 in total

Review 1.  Adverse effects of intravenous immunoglobulin therapy.

Authors:  U E Nydegger; M Sturzenegger
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

Review 2.  Criteria for the appropriate drug utilisation of immunoglobulin.

Authors:  P Thürmann; S Harder
Journal:  Pharmacoeconomics       Date:  1996-05       Impact factor: 4.981

Review 3.  Human Immunoglobulins for intravenous use and hepatitis C viral transmission.

Authors:  H B Slade
Journal:  Clin Diagn Lab Immunol       Date:  1994-11

4.  Intravenous immunoglobulin in the treatment of paediatric cerebral malaria.

Authors:  T E Taylor; M E Molyneux; J J Wirima; A Borgstein; J D Goldring; M Hommel
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

5.  Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.

Authors:  Daniel Suez; Mark Stein; Sudhir Gupta; Iftikhar Hussain; Isaac Melamed; Kenneth Paris; Amy Darter; Christelle Bourgeois; Sandor Fritsch; Heinz Leibl; Barbara McCoy; David Gelmont; Leman Yel
Journal:  J Clin Immunol       Date:  2016-08-31       Impact factor: 8.317

Review 6.  Virus safety of intravenous immunoglobulin: future challenges.

Authors:  Nicola Boschetti; Martin Stucki; Peter J Späth; Christoph Kempf
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

7.  Safety of snake antivenom immunoglobulins: efficacy of viral inactivation in a complete downstream process.

Authors:  C P Caricati; L Oliveira-Nascimento; J T Yoshida; A T P Caricati; I Raw; M A Stephano
Journal:  Biotechnol Prog       Date:  2013-06-27

8.  Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.

Authors:  M Borte; G Kriván; B Derfalvi; L Maródi; T Harrer; S Jolles; C Bourgeois; W Engl; H Leibl; B McCoy; D Gelmont; L Yel
Journal:  Clin Exp Immunol       Date:  2016-10-18       Impact factor: 4.330

9.  Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins.

Authors:  Christoph Kempf; Martin Stucki; Nicola Boschetti
Journal:  Biologicals       Date:  2006-04-03       Impact factor: 1.856

Review 10.  Intravenous immunoglobulins: evolution of commercial IVIG preparations.

Authors:  John A Hooper
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.